当前位置: 首页 >> 检索结果
181. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
作者: Ankit Bhardwaj.;Chandan Kumar Kedarisetty.;Chitranshu Vashishtha.;Ajeet Singh Bhadoria.;Ankur Jindal.;Guresh Kumar.;Ashok Choudhary.;S M Shasthry.;Rakhi Maiwall.;Manoj Kumar.;Vikram Bhatia.;Shiv Kumar Sarin.
来源: Gut. 2017年66卷10期1838-1843页
Carvedilol is effective in the primary prophylaxis for large oesophageal varices. We investigated its use in preventing progression of small to large oesophageal varices.
182. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis.
作者: Alfred D Nelson.;Michael Camilleri.;Sakkarin Chirapongsathorn.;Priya Vijayvargiya.;Nelson Valentin.;Andrea Shin.;Patricia J Erwin.;Zhen Wang.;M Hassan Murad.
来源: Gut. 2017年66卷9期1611-1622页
To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis.
183. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
作者: Sue Moss.;Christopher Mathews.;T J Day.;Steve Smith.;Helen E Seaman.;Julia Snowball.;Stephen P Halloran.
来源: Gut. 2017年66卷9期1631-1644页
The National Health Service Bowel Cancer Screening Programme (BCSP) in England uses a guaiac-based faecal occult blood test (gFOBt). A quantitative faecal immunochemical test (FIT) for haemoglobin (Hb) has many advantages, including being specific for human blood, detecting Hb at a much lower concentration with a single faecal sample and improved uptake.
184. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.
作者: Pål Møller.;Toni Seppälä.;Inge Bernstein.;Elke Holinski-Feder.;Paola Sala.;D Gareth Evans.;Annika Lindblom.;Finlay Macrae.;Ignacio Blanco.;Rolf Sijmons.;Jacqueline Jeffries.;Hans Vasen.;John Burn.;Sigve Nakken.;Eivind Hovig.;Einar Andreas Rødland.;Kukatharmini Tharmaratnam.;Wouter H de Vos Tot Nederveen Cappel.;James Hill.;Juul Wijnen.;Mark Jenkins.;Kate Green.;Fiona Lalloo.;Lone Sunde.;Miriam Mints.;Lucio Bertario.;Marta Pineda.;Matilde Navarro.;Monika Morak.;Laura Renkonen-Sinisalo.;Ian M Frayling.;John-Paul Plazzer.;Kirsi Pylvanainen.;Maurizio Genuardi.;Jukka-Pekka Mecklin.;Gabriela Möslein.;Julian R Sampson.;Gabriel Capella.; .
来源: Gut. 2017年66卷9期1657-1664页
Today most patients with Lynch syndrome (LS) survive their first cancer. There is limited information on the incidences and outcome of subsequent cancers. The present study addresses three questions: (i) what is the cumulative incidence of a subsequent cancer; (ii) in which organs do subsequent cancers occur; and (iii) what is the survival following these cancers?
185. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus.
作者: Kwong Ming Fock.;Nicholas Talley.;Khean Lee Goh.;Kentaro Sugano.;Peter Katelaris.;Gerald Holtmann.;John E Pandolfino.;Prateek Sharma.;Tiing Leong Ang.;Michio Hongo.;Justin Wu.;Minhu Chen.;Myung-Gyu Choi.;Ngai Moh Law.;Bor-Shyang Sheu.;Jun Zhang.;Khek Yu Ho.;Jose Sollano.;Abdul Aziz Rani.;Chomsri Kositchaiwat.;Shobna Bhatia.
来源: Gut. 2016年65卷9期1402-15页
Since the publication of the Asia-Pacific consensus on gastro-oesophageal reflux disease in 2008, there has been further scientific advancement in this field. This updated consensus focuses on proton pump inhibitor-refractory reflux disease and Barrett's oesophagus.
189. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.
作者: Daniel Todt.;Anett Gisa.;Aleksandar Radonic.;Andreas Nitsche.;Patrick Behrendt.;Pothakamuri Venkata Suneetha.;Sven Pischke.;Birgit Bremer.;Richard J P Brown.;Michael P Manns.;Markus Cornberg.;C Thomas Bock.;Eike Steinmann.;Heiner Wedemeyer.
来源: Gut. 2016年65卷10期1733-43页
Hepatitis E virus (HEV) infection can take chronic courses in immunocompromised patients potentially leading to liver cirrhosis and liver failure. Ribavirin (RBV) is currently the only treatment option for many patients, but treatment failure can occur which has been associated with the appearance of a distinct HEV polymerase mutant (G1634R). Here, we performed a detailed analysis of HEV viral intrahost evolution during chronic hepatitis E infections.
190. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption.
作者: Nicolas Calo.;Pierluigi Ramadori.;Cyril Sobolewski.;Yannick Romero.;Christine Maeder.;Margot Fournier.;Pia Rantakari.;Fu-Ping Zhang.;Matti Poutanen.;Jean-François Dufour.;Bostjan Humar.;Serge Nef.;Michelangelo Foti.
来源: Gut. 2016年65卷11期1871-1881页
miR-21 is an oncomir highly upregulated in hepatocellular carcinoma and in early stages of liver diseases characterised by the presence of steatosis. Whether upregulation of miR-21 contributes to hepatic metabolic disorders and their progression towards cancer is unknown. This study aims at investigating the role of miR-21/miR-21* in early stages of metabolic liver disorders associated with diet-induced obesity (DIO).
191. Refinement of screening for familial pancreatic cancer.
作者: D K Bartsch.;E P Slater.;A Carrato.;I S Ibrahim.;C Guillen-Ponce.;H F A Vasen.;E Matthäi.;J Earl.;F S Jendryschek.;J Figiel.;M Steinkamp.;A Ramaswamy.;E Vázquez-Sequeiros.;M Muñoz-Beltran.;J Montans.;E Mocci.;B A Bonsing.;M Wasser.;G Klöppel.;P Langer.;V Fendrich.;T M Gress.
来源: Gut. 2016年65卷8期1314-21页
Surveillance programmes are recommended for individuals at risk (IAR) of familial pancreatic cancer (FPC) to detect early pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). However, the age to begin screening and the optimal screening protocol remain to be determined.
192. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC.
作者: Amanda E Starr.;Shelley A Deeke.;Zhibin Ning.;Cheng-Kang Chiang.;Xu Zhang.;Walid Mottawea.;Ruth Singleton.;Eric I Benchimol.;Ming Wen.;David R Mack.;Alain Stintzi.;Daniel Figeys.
来源: Gut. 2017年66卷9期1573-1583页
Accurate differentiation between Crohn's disease (CD) and UC is important to ensure early and appropriate therapeutic intervention. We sought to identify proteins that enable differentiation between CD and UC in children with new onset IBD.
194. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
作者: João Sabino.;Sara Vieira-Silva.;Kathleen Machiels.;Marie Joossens.;Gwen Falony.;Vera Ballet.;Marc Ferrante.;Gert Van Assche.;Schalk Van der Merwe.;Severine Vermeire.;Jeroen Raes.
来源: Gut. 2016年65卷10期1681-9页
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease often leading to end-stage liver disease. Its pathogenesis remains largely unknown, although frequent concomitant IBD hints towards common factors underlying gut and bile duct inflammation. Considering the mounting evidence on the involvement of the intestinal microbiota in initiating and determining IBD phenotype, we investigated intestinal microbiota composition in patients with PSC.
195. Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins.
作者: Ralf Kuja-Halkola.;Benjamin Lebwohl.;Jonas Halfvarson.;Cisca Wijmenga.;Patrik K E Magnusson.;Jonas F Ludvigsson.
来源: Gut. 2016年65卷11期1793-1798页
Almost 100% individuals with coeliac disease (CD) are carriers of the human leucocyte antigen (HLA) DQ2/DQ8 alleles. Earlier studies have, however, failed to consider the HLA system when estimating heritability in CD, thus violating an underlying assumption of heritability analysis. We examined the heritability of CD in a large population-based sample of twins, considering HLA.
198. Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.
作者: Kazunari Murakami.;Yuuichi Sakurai.;Madoka Shiino.;Nobuo Funao.;Akira Nishimura.;Masahiro Asaka.
来源: Gut. 2017年66卷2期386页 200. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
作者: Yan-Yi Jiang.;De-Chen Lin.;Anand Mayakonda.;Masaharu Hazawa.;Ling-Wen Ding.;Wen-Wen Chien.;Liang Xu.;Ye Chen.;Jin-Fen Xiao.;William Senapedis.;Erkan Baloglu.;Deepika Kanojia.;Li Shang.;Xin Xu.;Henry Yang.;Jeffrey W Tyner.;Ming-Rong Wang.;H Phillip Koeffler.
来源: Gut. 2017年66卷8期1358-1368页
Oesophageal squamous cell carcinoma (OSCC) is an aggressive malignancy and the major histological subtype of oesophageal cancer. Although recent large-scale genomic analysis has improved the description of the genetic abnormalities of OSCC, few targetable genomic lesions have been identified, and no molecular therapy is available. This study aims to identify druggable candidates in this tumour.
|